Morgan Stanley’s NRX Pharmaceuticals NRXP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $14.3K | Sell |
4,396
-7,500
| -63% | -$24.5K | ﹤0.01% | 6760 |
|
|
2025
Q1 | $24.4K | Buy |
11,896
+7,500
| +171% | +$15.4K | ﹤0.01% | 6499 |
|
|
2024
Q4 | $9.67K | Hold |
4,396
| – | – | ﹤0.01% | 6816 |
|
|
2024
Q3 | $7.43K | Hold |
4,396
| – | – | ﹤0.01% | 6798 |
|
|
2024
Q2 | $10.7K | Buy |
4,396
+1
| +0% | +$2 | ﹤0.01% | 6661 |
|
|
2024
Q1 | $20.7K | Sell |
4,395
-4,472
| -50% | -$21.1K | ﹤0.01% | 6477 |
|
|
2023
Q4 | $40.8K | Buy |
8,867
+4,134
| +87% | +$19K | ﹤0.01% | 6443 |
|
|
2023
Q3 | $12.3K | Hold |
4,733
| – | – | ﹤0.01% | 6655 |
|
|
2023
Q2 | $22.9K | Hold |
4,733
| – | – | ﹤0.01% | 6527 |
|
|
2023
Q1 | $31.2K | Sell |
4,733
-301
| -6% | -$1.98K | ﹤0.01% | 6456 |
|
|
2022
Q4 | $55.9K | Sell |
5,034
-897
| -15% | -$9.96K | ﹤0.01% | 6246 |
|
|
2022
Q3 | $43K | Buy |
5,931
+294
| +5% | +$2.13K | ﹤0.01% | 6468 |
|
|
2022
Q2 | $33K | Buy |
5,637
+457
| +9% | +$2.68K | ﹤0.01% | 6800 |
|
|
2022
Q1 | $128K | Sell |
5,180
-554
| -10% | -$13.7K | ﹤0.01% | 6167 |
|
|
2021
Q4 | $274K | Buy |
5,734
+1,629
| +40% | +$77.8K | ﹤0.01% | 5891 |
|
|
2021
Q3 | $381K | Buy |
4,105
+118
| +3% | +$11K | ﹤0.01% | 5655 |
|
|
2021
Q2 | $463K | Buy |
3,987
+3,920
| +5,851% | +$455K | ﹤0.01% | 5570 |
|
|
2021
Q1 | $24K | Sell |
67
-69
| -51% | -$24.7K | ﹤0.01% | 6663 |
|
|
2020
Q4 | $33K | Buy |
+136
| New | +$33K | ﹤0.01% | 6290 |
|